Alzheimer’s disease(AD) is the most common form of dementia. In the past few decades, great advances have been made in the understanding of its pathophysiology due to the use of biomarkers. Imaging biomarkers, either based on structural brain changes and metabolic alterations alone, or in conjunction with cerebrospinal fluid(CSF) biomarkers, can be informative of the ongoing pathological processes occurring in a patient with AD. In our method, we propose a novel MRI biomarker that is based on the extraction of structural features from a T1-w MRI scan, and it provides biological characterization of early and later forms of AD.
This abstract and the presentation materials are available to members only; a login is required.